Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alliant Energy Corporation (LNT) vs Merck & Co., Inc. (MRK) Price & Performance

Alliant Energy CorporationTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Alliant Energy Corporation vs Merck & Co., Inc. — how do they compare? Alliant Energy Corporation trades at $65.85 (market cap $16.99B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 20.7× Alliant Energy Corporation's market cap, and Alliant Energy Corporation pays the higher dividend (3.27%). Which is the better fit depends on your goals — on Pluang, investors hold Alliant Energy Corporation for 64 Days and Merck & Co., Inc. for 98 Days on average.

LNTMRK
Market Cap
$16.99B$351.28B
Volume
2,488,3877,969,665
Sector
UtilitiesHealth
52-Week High
$78.03$156.43
52-Week Low
$63.21$82.49
Typical Hold Time
64 Days98 Days
Enterprise Value
$29.08B$398.04B
Dividend Yield
3.27%2.39%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alliant Energy Corporation

LNT trades at $65.84, up 0.97% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong earnings beats in recent quarters and maintains solid profitability with an 18.45% net margin. Analyst consensus is bullish with a $77 price target, and institutional interest remains high, evidenced by recent large purchases.

LNT's outlook is supported by a $13.4 billion capital investment plan and growing data center demand, though rising debt levels and competitive pressures present risks. The stock offers a defensive income stream with a consistent dividend, but investors should monitor execution of growth initiatives amid economic uncertainty.

Merck & Co., Inc.

Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.

The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LNT

No sentiment data available yet.

MRK
60% Buy40% Sell
Avg holding period · 98 Days

Top news

Latest headlines on both assets

About Alliant Energy Corporation

Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.

Read more on LNT →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK →